Staff Reporter :
Beximco Pharmaceuticals Limited, one of Bangladesh’s largest drugmakers, announced on Friday that it will invest with the Serum Institute of India (SII) to get access to Covid-19 vaccines it is developing for the novel coronavirus.
The deal comes after Bangladesh said this month it was ready to hold trials of candidate vaccines developed by India as both countries seek to curb the spread of the virus.
“The investment amount will be treated as an advance and once the vaccine receives regulatory approvals, SII will include Bangladesh among the countries who will be the first to receive an agreed quantity of this vaccine from SII on a priority basis,” Beximco said in a statement, citing the heads of both organisations.
It said Beximco will also be the exclusive supplier for Bangladesh for a vaccine developed by the Serum Institute, which has already partnered with Oxford/AstraZeneca along with Gates Foundation and Gavi, to produce more than a billion doses of the vaccine for global supply.
Both Adar C Poonawalla, Owner and CEO of SII and Shayan F Rahman, Principal, BPL jointly commented, “We are excited to bring together two of the leading pharma companies in India and Bangladesh with the scale and capabilities to bring a hugely promising treatment to the people who need it the most.”
The Serum Institute, the world’s largest manufacturer of vaccines by volume, is holding trials for three potential coroanvirus vaccines, including one licensed to AstraZeneca Plc by Oxford University.
The Oxford/AstraZeneca vaccine (AZD1222) is an adenovirus vector-based vaccine, currently undergoing large scale phase III trials in Brazil, US, UK and India. The UK trials are well underway and have shown very encouraging results and are
expected to receive approval by the end of 2020.
Bangladesh also approved a late-stage trial of a potential coronavirus vaccine developed by China’s Sinovac Biotech Ltd in the hope of being a priority recipient for the jab.
Bangladesh confirmed 47 more deaths and reported 2,211 new cases on Friday, taking the total number of cases in the country to 306,794 with 4,174 deaths.
India reported a record daily jump of 77,266 coronavirus infections on Friday, taking its total number of cases to 3.39 million with 61,529 deaths.
Beximco Pharmaceuticals Limited, one of Bangladesh’s largest drugmakers, announced on Friday that it will invest with the Serum Institute of India (SII) to get access to Covid-19 vaccines it is developing for the novel coronavirus.
The deal comes after Bangladesh said this month it was ready to hold trials of candidate vaccines developed by India as both countries seek to curb the spread of the virus.
“The investment amount will be treated as an advance and once the vaccine receives regulatory approvals, SII will include Bangladesh among the countries who will be the first to receive an agreed quantity of this vaccine from SII on a priority basis,” Beximco said in a statement, citing the heads of both organisations.
It said Beximco will also be the exclusive supplier for Bangladesh for a vaccine developed by the Serum Institute, which has already partnered with Oxford/AstraZeneca along with Gates Foundation and Gavi, to produce more than a billion doses of the vaccine for global supply.
Both Adar C Poonawalla, Owner and CEO of SII and Shayan F Rahman, Principal, BPL jointly commented, “We are excited to bring together two of the leading pharma companies in India and Bangladesh with the scale and capabilities to bring a hugely promising treatment to the people who need it the most.”
The Serum Institute, the world’s largest manufacturer of vaccines by volume, is holding trials for three potential coroanvirus vaccines, including one licensed to AstraZeneca Plc by Oxford University.
The Oxford/AstraZeneca vaccine (AZD1222) is an adenovirus vector-based vaccine, currently undergoing large scale phase III trials in Brazil, US, UK and India. The UK trials are well underway and have shown very encouraging results and are
expected to receive approval by the end of 2020.
Bangladesh also approved a late-stage trial of a potential coronavirus vaccine developed by China’s Sinovac Biotech Ltd in the hope of being a priority recipient for the jab.
Bangladesh confirmed 47 more deaths and reported 2,211 new cases on Friday, taking the total number of cases in the country to 306,794 with 4,174 deaths.
India reported a record daily jump of 77,266 coronavirus infections on Friday, taking its total number of cases to 3.39 million with 61,529 deaths.
